Hikma Pharmaceuticals PLC (LON:HIK – Get Free Report) passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of GBX 1,921.37 ($24.95) and traded as high as GBX 2,022 ($26.25). Hikma Pharmaceuticals shares last traded at GBX 1,997 ($25.93), with a volume of 189,613 shares changing hands.
Wall Street Analysts Forecast Growth
Separately, Berenberg Bank upgraded Hikma Pharmaceuticals to a “buy” rating and upped their price target for the stock from GBX 2,100 ($27.27) to GBX 2,400 ($31.16) in a research note on Monday, September 2nd.
Get Our Latest Stock Report on HIK
Hikma Pharmaceuticals Stock Down 0.1 %
Hikma Pharmaceuticals Cuts Dividend
The business also recently disclosed a dividend, which was paid on Friday, September 20th. Stockholders of record on Thursday, August 15th were given a dividend of $0.32 per share. This represents a dividend yield of 1.37%. The ex-dividend date was Thursday, August 15th. Hikma Pharmaceuticals’s dividend payout ratio is currently 9,538.46%.
Hikma Pharmaceuticals Company Profile
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.
Further Reading
- Five stocks we like better than Hikma Pharmaceuticals
- How to Calculate Stock Profit
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- Stock Average Calculator
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.